A gas chromatography-mass spectrometry (GC-MS) method for the simultaneous determination of 5'-deoxy-Sfluorouridine (doxifluridine, 5'-dFUR), 5fluorouracil (5-FU) and its main catabolite 5,6-dihydro-5-fluorouracil (5-FUH\*) in human plasma has been developed. Sample preparation consisted of protein
Non-linear pharmacokihetics of 5-fluorouracil as described by in vivo behaviour of 5,6 dihydro-5-fluorouracil
β Scribed by E.A. De Bruijn; L. Remeyer; U.R. Tjaden; C. Erkelens; L.M. De Brauw; C.J.H. Van De Velde
- Book ID
- 115778716
- Publisher
- Elsevier Science
- Year
- 1986
- Tongue
- English
- Weight
- 433 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0006-2952
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Dihydro-5-fluorouracluorouracil(5-lWH~) , the maiu catabolite of the anticancer drug 54uorouraeil( WU), can be quantitated iu human serum simultaueously with the pro-drug 5'-deoxy-5-f (5'dFWR), the parent drug 5-PU and the aaabolites 5-fluorouridine and 2'-deoxy-5-f by gradient elution-reversed phas
## Abstract A uridine phosphorylase inhibitor, 5βbenzylacyclouridine (BAU), has been utilized as biochemical modulator of 5βfluorouracil (5βFU) antiβtumor activity in a murine tumor model. The effect of BAU on 5βFU metabolism has been evaluated using __in vitro__ and __in vivo__ ^19^F NMR spectrosc